What's in Ivan Šitum, MD's pipeline?

Ivan Šitum, MD has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Ivan Šitum, MD's portfolio?

Top competitors by shared drug class: Ain Shams University, Merck Sharp & Dohme LLC, National University of Singapore, Qilu Pharmaceutical Co., Ltd., Southeast University, China.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ivan-itum-md.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Ivan Šitum, MD — Portfolio Competitive Intelligence Brief

Ivan Šitum, MD pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Intermitent dosing as per SMPC	Intermitent dosing as per SMPC	marketed
Continuos ceftazidime/avibactam infusion	Continuos ceftazidime/avibactam infusion	marketed	Beta-lactam/beta-lactamase inhibitor combination	Penicillin-binding proteins (PBPs); serine beta-lactamases	Infectious Disease

Therapeutic area mix

Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Ain Shams University · 1 shared drug class
Merck Sharp & Dohme LLC · 1 shared drug class
National University of Singapore · 1 shared drug class
Qilu Pharmaceutical Co., Ltd. · 1 shared drug class
Southeast University, China · 1 shared drug class
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · 1 shared drug class
Wockhardt · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Ivan Šitum, MD:

Cite this brief

Drug Landscape (2026). Ivan Šitum, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ivan-itum-md. Accessed 2026-05-14.